In this study, we developed an electrochemical sensor for the sensitive voltammetric determination of Baricitinib (BCT), a recently FDA-approved medication for curing COVID-19. Voltammetric measurements were employed using a carbon paste electrode modified with zinc oxide and iron oxide nanoparticles (ZnO/α-Fe2O3-NPs/CPE). The composition of the fabricated electrode was optimized, and the best sensitivity was achieved by utilizing 5% of ZnO/α-Fe2O3-NPs, which maximized the electroactive surface area. The final optimized electrode was electrochemically and physicochemically characterized by exploiting the following techniques: X-ray diffraction (XRD) patterns, scanning electron microscopy (SEM), transmission electron microscopy (TEM), energy dispersive X-ray analysis (EDX), and X-ray photoelectron spectroscopy (XPS). All experimental parameters, including the pH and scan rate, have been studied and optimized. The proposed sensor was successfully employed for BCT analysis by square wave voltammetry (SWV), and the attained linear dynamic range was (8.0 × 10−8 – 1.0 × 10−6 mol L−1), and the estimated limit of detection (LOD) and limit of quantitation (LOQ) were 1.799 × 10−8 mol L−1 and 5.453 × 10−8 mol L−1, respectively. The suggested electrochemical methodology was effectively utilized to determine BCT with satisfactory percentage recoveries in pharmaceutical preparation (99.69% ± 0.73) and human plasma samples. The developed approach underwent validation and was determined to be reproducible (RSD = 0.75%) and accurate (99.68% ± 0.76) following the ICH recommendations. The greenness of the established electrochemical protocol was assessed utilizing the Analytical Eco-Scale and Analytical GREEnness Metric Approach (AGREE).
Read full abstract